Integrating Omics Data and AI for Cancer Diagnosis and Prognosis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jul 13

PMID 39001510

Authors

Yousaku Ozaki

Phil Broughton

Hamed Abdollahi

Homayoun Valafar

Anna V Blenda

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the leading causes of death, making timely diagnosis and prognosis very important. Utilization of AI (artificial intelligence) enables providers to organize and process patient data in a way that can lead to better overall outcomes. This review paper aims to look at the varying uses of AI for diagnosis and prognosis and clinical utility. PubMed and EBSCO databases were utilized for finding publications from 1 January 2020 to 22 December 2023. Articles were collected using key search terms such as "artificial intelligence" and "machine learning." Included in the collection were studies of the application of AI in determining cancer diagnosis and prognosis using multi-omics data, radiomics, pathomics, and clinical and laboratory data. The resulting 89 studies were categorized into eight sections based on the type of data utilized and then further subdivided into two subsections focusing on cancer diagnosis and prognosis, respectively. Eight studies integrated more than one form of omics, namely genomics, transcriptomics, epigenomics, and proteomics. Incorporating AI into cancer diagnosis and prognosis alongside omics and clinical data represents a significant advancement. Given the considerable potential of AI in this domain, ongoing prospective studies are essential to enhance algorithm interpretability and to ensure safe clinical integration.

Citing Articles

AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis.

Alum E Discov Oncol. 2025; 16(1):313.

PMID: 40082367 PMC: 11906928. DOI: 10.1007/s12672-025-02064-7.

Integrating AI into Cancer Immunotherapy-A Narrative Review of Current Applications and Future Directions.

Olawade D, Clement David-Olawade A, Adereni T, Egbon E, Teke J, Boussios S Diseases. 2025; 13(1).

PMID: 39851488 PMC: 11764268. DOI: 10.3390/diseases13010024.

Mechanisms and technologies in cancer epigenetics.

Sherif Z, Ogunwobi O, Ressom H Front Oncol. 2025; 14:1513654.

PMID: 39839798 PMC: 11746123. DOI: 10.3389/fonc.2024.1513654.

Impact of Metabolites from Foodborne Pathogens on Cancer.

Mafe A, Busselberg D Foods. 2024; 13(23).

PMID: 39682958 PMC: 11640045. DOI: 10.3390/foods13233886.

Artificial Intelligence-Driven Computational Approaches in the Development of Anticancer Drugs.

Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal S Cancers (Basel). 2024; 16(22).

PMID: 39594838 PMC: 11593155. DOI: 10.3390/cancers16223884.

References

Yu P, Wu X, Li J, Mao N, Zhang H, Zheng G . Extrathyroidal Extension Prediction of Papillary Thyroid Cancer With Computed Tomography Based Radiomics Nomogram: A Multicenter Study. Front Endocrinol (Lausanne). 2022; 13:874396. PMC: 9198261. DOI: 10.3389/fendo.2022.874396. View

Carrillo-Perez F, Ortuno F, Borjesson A, Rojas I, Herrera L . Performance comparison between multi-center histopathology datasets of a weakly-supervised deep learning model for pancreatic ductal adenocarcinoma detection. Cancer Imaging. 2023; 23(1):66. PMC: 10294485. DOI: 10.1186/s40644-023-00586-3. View

Hasin Y, Seldin M, Lusis A . Multi-omics approaches to disease. Genome Biol. 2017; 18(1):83. PMC: 5418815. DOI: 10.1186/s13059-017-1215-1. View

Jin Y, Lan A, Dai Y, Jiang L, Liu S . Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy. Eur J Med Res. 2023; 28(1):394. PMC: 10543332. DOI: 10.1186/s40001-023-01361-7. View

Owens A, McInerney C, Prise K, McArt D, Jurek-Loughrey A . Novel deep learning-based solution for identification of prognostic subgroups in liver cancer (Hepatocellular carcinoma). BMC Bioinformatics. 2021; 22(1):563. PMC: 8611905. DOI: 10.1186/s12859-021-04454-4. View

Feldner-Busztin D, Firbas Nisantzis P, Edmunds S, Boza G, Racimo F, Gopalakrishnan S . Dealing with dimensionality: the application of machine learning to multi-omics data. Bioinformatics. 2023; 39(2). PMC: 9907220. DOI: 10.1093/bioinformatics/btad021. View

Anderson A, Grazal C, Wedin R, Kuo C, Chen Y, Christensen B . Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool. BMC Cancer. 2022; 22(1):476. PMC: 9055684. DOI: 10.1186/s12885-022-09491-7. View

Gao L, Lin Y, Yue P, Li S, Zhang Y, Mi N . Identification of a novel bile marker clusterin and a public online prediction platform based on deep learning for cholangiocarcinoma. BMC Med. 2023; 21(1):294. PMC: 10408060. DOI: 10.1186/s12916-023-02990-9. View

Tang Y, Yang C, Su S, Wang W, Fan L, Shu J . Machine learning-based Radiomics analysis for differentiation degree and lymphatic node metastasis of extrahepatic cholangiocarcinoma. BMC Cancer. 2021; 21(1):1268. PMC: 8611922. DOI: 10.1186/s12885-021-08947-6. View

10.

Zhang H, Ji J, Liu Z, Lu H, Qian C, Wei C . Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study. BMC Med. 2023; 21(1):270. PMC: 10367399. DOI: 10.1186/s12916-023-02964-x. View

11.

Liu T, Dong D, Zhao X, Ou X, Yi J, Guan J . Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study. BMC Med. 2023; 21(1):464. PMC: 10683300. DOI: 10.1186/s12916-023-03164-3. View

12.

Zeng Z, Luo M, Li Y, Li J, Huang Z, Zeng Y . Prediction of radiosensitivity and radiocurability using a novel supervised artificial neural network. BMC Cancer. 2022; 22(1):1243. PMC: 9713966. DOI: 10.1186/s12885-022-10339-3. View

13.

Ravkin H, Givton O, Geffen D, Rubin E . Direct comparison shows that mRNA-based diagnostics incorporate information which cannot be learned directly from genomic mutations. BMC Bioinformatics. 2020; 21(1):196. PMC: 7236449. DOI: 10.1186/s12859-020-3512-z. View

14.

Javaid H, Barberis A, Chervova O, Nassiri I, Voloshin V, Sato Y . A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation. BMC Cancer. 2023; 23(1):721. PMC: 10394884. DOI: 10.1186/s12885-023-11162-0. View

15.

Jiang Y, Yan X, Liu K, Shi Y, Wang C, Hu J . Discovering the molecular differences between right- and left-sided colon cancer using machine learning methods. BMC Cancer. 2020; 20(1):1012. PMC: 7574488. DOI: 10.1186/s12885-020-07507-8. View

16.

Sugino R, Ohira M, Mansai S, Kamijo T . Comparative epigenomics by machine learning approach for neuroblastoma. BMC Genomics. 2022; 23(1):852. PMC: 9793522. DOI: 10.1186/s12864-022-09061-y. View

17.

Liang W, Tian W, Wang Y, Wang P, Wang Y, Zhang H . Classification prediction of pancreatic cystic neoplasms based on radiomics deep learning models. BMC Cancer. 2022; 22(1):1237. PMC: 9710154. DOI: 10.1186/s12885-022-10273-4. View

18.

Fu Y, Si A, Wei X, Lin X, Ma Y, Qiu H . Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma. BMC Genomics. 2023; 24(1):89. PMC: 9972730. DOI: 10.1186/s12864-023-09194-8. View

19.

Huang Y, Feng A, Lin Y, Gu H, Chen H, Wang H . Radiation pneumonitis prediction after stereotactic body radiation therapy based on 3D dose distribution: dosiomics and/or deep learning-based radiomics features. Radiat Oncol. 2022; 17(1):188. PMC: 9673306. DOI: 10.1186/s13014-022-02154-8. View

20.

Meng B, Li G, Zeng Z, Zheng B, Xia Y, Li C . Establishment of early diagnosis models for cervical precancerous lesions using large-scale cervical cancer screening datasets. Virol J. 2022; 19(1):177. PMC: 9636682. DOI: 10.1186/s12985-022-01908-w. View